Restless Leg Syndrome (RLS) Therapeutics – Pipeline Assessment and Market Forecasts to 2017
RLS Therapeutics Market Forecast to Demonstrate Steady Growth until 2017
6/29/2011 12:00:00 AM
GlobalData estimates that the Restless Leg Syndrome Therapeutics (RLS) market was valued at $360m
in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.4% over the next
seven years, to reach $766m by 2017. This steady growth is primarily attributed to an increasing patient
pool, the launch of Horizant (gabapentin enacarbil) by GlaxoSmithKline in Q2 2011 and the anticipated
launch of Neupro (rotigotine) in the US by UCB S.A. in 2012. However, the low treatment seeking
population, low disease awareness and use of generic drugs in the treatment of RLS may act as barriers
to market growth.
GlobalData’s research indicates that the current RLS therapeutics provide only symptomatic relief. The
marketed drugs include Mirapex (pramipexole) and Requip (ropinirole) and recently approved Horizant
(2011). As a result, the unmet need of the RLS market is estimated to be high, as the market requires
novel therapies which offer better results in terms of safety and efficacy.
GlobalData’s analysis indicates that the current competition in the RLS therapeutics market is weak, and
that the available treatment options have been moderately successful in meeting market need. The
currently marketed products, including Mirapex and Requip, are moderately successful in treating the
symptoms of the disease. However, with the entry of Horizant, approved in April 2011, competition in the market is expected to intensify as it has demonstrated an improved bioavailability and efficacy profile in comparison with Mirapex and Requip. GlaxoSmithKline Plc. (GSK), UCB S.A. Otsuka Pharmaceuticals and Boehringer Ingelheim will be the key companies in the future RLS market.
For Sample Pages, please click or add the below link to your browser:
GlobalData analysis demonstrates the weakness of the RLS therapeutics pipeline, with only five
molecules in various phases of development. The pipeline consists of molecules which can provide
symptomatic relief, but not complete disease cure, and there is one me-too molecule, rotigotine, which is under the New Drug Application (NDA) filing stage in the US and in Phase III of Japan. First-in-class
products are present in Phase III (rasagiline) and Phase II (aplindore) of the RLS therapeutics pipeline.
There are no molecules in Phase I of clinical development, and only one molecule, PDE7, is in the preclinical stage.
GlobalData, the industry analysis specialist, has released its new report, “Restless Leg Syndrome (RLS)
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global therapeutics market. The report identifies the key trends shaping and driving the global restless leg syndrome therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global restless leg syndrome therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/reportstore
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
Visit Our Site
Get your Press release distributed to 90+ PR directories and 100’s of Journalists.
FREE featured news at PRBD.NET, PR4links.com and Sardnews.org worth $27.